MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)’s stock price traded down 9.3% during trading on Friday . The stock traded as low as $5.50 and last traded at $5.56. 3,514 shares were traded during trading, a decline of 99% from the average session volume of 658,173 shares. The stock had previously closed at $6.13.
Wall Street Analysts Forecast Growth
Separately, BTIG Research increased their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a “buy” rating in a report on Sunday, August 14th.
MaxCyte Stock Down 5.9 %
The company has a 50-day simple moving average of $5.62.
Insider Transactions at MaxCyte
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MXCT. Quantbot Technologies LP acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $27,000. Freemont Management S.A. acquired a new stake in shares of MaxCyte in the 1st quarter valued at about $68,000. Nkcfo LLC acquired a new stake in shares of MaxCyte in the 1st quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $76,000. Finally, PDT Partners LLC acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $76,000. 66.40% of the stock is currently owned by institutional investors.
MaxCyte Company Profile
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.